Retention of γH2AX foci as an indication of lethal DNA damage

Abstract The application of biological responses of tumours to predict clinical responses to treatment represents a challenging goal with the potential to inform treatment decisions and improve outcome. If tumour cell death is the result of the inability of a cell to repair complex DNA damage, and i...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2011-10, Vol.101 (1), p.18-23
Main Author: Olive, Peggy L
Format: Article
Language:English
Subjects:
Apoptosis - genetics
Apoptosis - radiation effects
Biomarkers, Tumor - analysis
Cell Death - genetics
Cell Death - radiation effects
Cell Line, Tumor
Chemoradiotherapy
DNA Breaks, Double-Stranded
DNA damage
DNA Damage - genetics
DNA Repair - genetics
DNA Repair - physiology
Drug Resistance, Neoplasm
Flow Cytometry
Gene Targeting - methods
Hematology, Oncology and Palliative Medicine
Histones - analysis
Histones - radiation effects
Humans
Neoplasms - chemistry
Neoplasms - genetics
Neoplasms - therapy
Prediction
Predictive Value of Tests
Radiation Dosage
Radiation, Ionizing
Treatment Outcome
Tumour response
γH2AX
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The application of biological responses of tumours to predict clinical responses to treatment represents a challenging goal with the potential to inform treatment decisions and improve outcome. If tumour cell death is the result of the inability of a cell to repair complex DNA damage, and if γH2AX foci mark sites of unrepaired double-strand breaks, then it may be possible to use residual γH2AX foci to identify treatment-resistant tumour cells early in the course of therapy. This review will highlight some of the evidence that supports the idea that residual γH2AX foci, within certain limitations, may be useful as an early indicator of tumour response to radiotherapy in situ , either alone or in combination with chemotherapy.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2011.05.055